UBS Maintains Neutral on AnaptysBio, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Neutral rating on AnaptysBio (NASDAQ:ANAB) and lowers the price target from $28 to $21.

November 01, 2023 | 6:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS has maintained a Neutral rating on AnaptysBio and lowered the price target from $28 to $21.
The lowered price target by UBS could potentially create a negative sentiment among investors, however, the maintained Neutral rating indicates that the stock is not expected to significantly outperform or underperform the market in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100